What is the likely underlying systemic condition in a 60-year-old man presenting with low-normal platelet count, Raynaud's phenomenon, plantar fasciitis, lateral epicondylitis, and occasional ocular migraines?

Systemic Sclerosis (Scleroderma) is the Most Likely Diagnosis

This constellation of symptoms—Raynaud's phenomenon, plantar fasciitis, epicondylitis (enthesitis), mild thrombocytopenia, and ocular migraines—strongly suggests an underlying connective tissue disease, most likely systemic sclerosis (SSc). The Raynaud's phenomenon is particularly telling, as it's the earliest manifestation of SSc in most patients 1.

Diagnostic Reasoning

Key Clinical Connections

The combination you're describing fits a systemic autoimmune process:

• Raynaud's phenomenon is present in >90% of SSc patients and typically appears years before other manifestations 2
• Enthesitis (plantar fasciitis and epicondylitis) indicates inflammatory involvement of connective tissue attachment sites, which occurs in SSc and overlapping autoimmune conditions
• Mild thrombocytopenia can occur in SSc due to platelet activation and consumption in the microvasculature 3
• Ocular migraines have a documented association with Raynaud's phenomenon and scleroderma, with one study showing 32% prevalence in SSc patients compared to 11% in controls 4. This likely reflects shared small vessel pathology

Critical Next Steps for Diagnosis

You need to immediately assess for:

1. Nailfold capillaroscopy - Look for dilated capillary loops, hemorrhages, and capillary loss (hallmark of SSc) 2

2. SSc-specific autoantibodies 2:

   • Anti-centromere antibodies (limited cutaneous SSc)
   • Anti-Scl-70/topoisomerase I (diffuse cutaneous SSc)
   • Anti-RNA polymerase III (diffuse SSc with renal crisis risk)
   • ANA (positive in >95% of SSc)

3. Assess for subclinical organ involvement 5:

   • Pulmonary function tests with DLCO - 23% have decreased diffusing capacity without symptoms
   • High-resolution chest CT - Screen for interstitial lung disease
   • Echocardiogram - Assess for pulmonary arterial hypertension
   • Esophageal manometry or barium swallow - 14% have esophageal dysmotility without symptoms
   • Renal function and urinalysis - 5% have renal involvement

4. Examine skin carefully for:

   • Skin thickening (especially fingers, hands, face)
   • Telangiectasias
   • Digital pitting scars
   • Calcinosis

Important Clinical Pitfalls

The severity of Raynaud's phenomenon correlates with extent of systemic involvement 5. More severe Raynaud's (measured by plethysmography) predicts more organ systems affected (r=0.38, p<0.01).

The number and titer of autoantibodies also correlates with systemic disease burden 5. Higher ANA titers and multiple autoantibodies predict more extensive organ involvement (r=0.65, p<0.01).

Rule Out Paraneoplastic Syndrome

While less likely given the age and symptom pattern, you must exclude underlying malignancy 6. The combination of fasciitis, Raynaud's phenomenon, and systemic symptoms can rarely represent paraneoplastic manifestations of:

• Ovarian cancer (palmar fasciitis with polyarthritis)
• Renal carcinoma (Raynaud's with digital ischemia)
• Anorectal tumors (diffuse SSc-like presentation)

Age-appropriate cancer screening is warranted, particularly if symptoms are rapidly progressive or atypical.

Immediate Management Considerations

For Raynaud's Phenomenon

First-line non-pharmacological management 1, 7:

• Strict cold avoidance and proper clothing (coat, mittens, hat, insulated footwear)
• Smoking cessation (critical)
• Avoid triggers: trauma, stress, certain drugs (bleomycin, clonidine, ergot alkaloids)
• Use of gloves and heating devices 7

Pharmacological treatment 1:

• First-line: Calcium channel blockers (typically nifedipine or amlodipine)
• Second-line: PDE5 inhibitors or IV prostacyclin analogues
• Third-line: Prostacyclin analogues

For Enthesitis

Standard anti-inflammatory management while working up the underlying systemic disease. If SSc is confirmed, the enthesitis may improve with disease-modifying treatment.

Monitoring Strategy

Given the correlation between autoantibody profiles and disease extent 5, the variety and titer of autoantibodies should guide your surveillance intensity. Patients with multiple autoantibodies and high titers require more aggressive screening for organ involvement.

The thrombocytopenia (if confirmed on repeat testing in heparin or citrate tubes to exclude pseudothrombocytopenia 8) likely reflects platelet activation and consumption in the microvasculature 3 rather than a primary hematologic disorder, but warrants monitoring.